Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Aarkstore enterprise---Therapeutic Monoclonal Antibodies Markets

Posted Oct 27 2010 1:07am

   

Table of Contents :

1. Introduction 5
1.1 Statement of Report 5
1.2 Objectives of this Report 5
1.3 Scope of the Report 6
1.4 Methodology 7
1.5 Executive Summary 8

2. The State of Therapeutic Monoclonal Antibody Technology 10
2.1 State of the Pharmaceutical Industry 10
2.2 Antibodies as an Alternative Pharmaceutical Agent 16
2.3 Current Status of Antibody Therapeutics 19
2.4 Demands of Antibody Therapeutics Development 23

3. Recent Technology Trends 24
3.1 Classic Design of Antibodies 24
3.1.1 Chimeric Monoclonal Antibodies 25
3.1.2 Humanized Monoclonal Antibodies 25
3.1.3 Totally Human Antibodies 26
3.1.4 Monoclonal Antibody Processing 26
3.2 Monoclonal Antibodies Therapeutics 26
3.2.1 Naked Monoclonal Antibodies 26
3.2.2 Conjugated Monoclonal Antibodies 27
3.3 Synthetic Antibodies, Unique Scaffolds 28
3.4 Screening and Selection of Antibodies 28
3.5 Novel Antibody Modifications: Glycosylation, Pegylation, Polymer Conjugations 29
3.5.1 Miniaturizing and Delivering Antibody Drugs 30
3.5.2 Recombinant Polyclonals 30
3.6 Monoclonal Antibody Purification 31

4. Industry Challenges 32
4.1 Introduction: Challenges Affecting the U.S. Therapeutic Monoclonal Antibodies Market 32
4.2 Increasing Costs and Complexities of Clinical Trials 33
4.3 Long-term Safety and Efficacy 33
4.3.1 Post-marketing Surveillance of Monoclonal Antibodies 34
4.4 High Cost of Monoclonal Antibodies 34
4.5 Restricted Government Healthcare Spending 35
4.6 Intellectual Property Thicket 35
4.7 Government Regulation 36
4.8 Third-party Reimbursement Environment 37

5. Pipeline Analysis 38
5.1 Overview of the Monoclonal Antibodies Pipeline 38
5.1.1 Anti-Cancer Antibodies 41
5.1.2 Profiles of Important Monoclonal Antibodies in Oncology 41
5.1.2.1 Avastin 42
5.1.2.2 Phase I Trials of Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy 44
5.1.2.3 Adecatumumab (MT201) in Combination with Chemotherapy 45
5.1.2.4 Herceptin 45
5.1.2.5 Pertuzumab, a HER2 Dimerization Inhibitor 46
5.1.2.6 Cetuximab 47
5.1.2.7 Prostate Cancer: Will Vaccines Lead the Way? 47
5.1.2.8 Recent Trial of an Anti-prostate Cancer Monoclonal Antibody 47
5.1.2.9 Anti-melanoma Antibodies 48
5.1.2.10 Other Anti-cancer Monoclonal Antibodies 48
5.1.3 Monoclonal Antibodies in Autoimmune and Inflammatory Disorders 48
5.1.3.1 Type 1 Diabetes 49
5.1.3.2 Rheumatoid Arthritis 49
5.1.4 Monoclonal Antibodies in Organ Transplants 50
5.1.5 Monoclonal Antibodies in Cardiovascular Disorders 50
5.1.5.1 Ablynx 50
5.1.5.2 ThromboGenics/BioInvent International 50
5.1.5.3 Pexelizumab: A Recombinant Humanized Single Chain Monoclonal Antibody 51
5.1.6 Monoclonal Antibodies in Infectious Diseases 51
5.1.7 Monoclonal Antibodies in Miscellaneous Indications 51
5.1.7.1 Alzheimer’s Disease 51
5.1.7.2 Parkinson’s Antibody Therapy 52
5.2 U.S. Therapeutic Monoclonal Antibodies Market 52
5.2.1 Market Dimensions 52

6. Short-term Market Predictions 54
6.1 Total Revenue Forecasts 54
6.2 Segment Revenue Forecast 55
6.2.1 Oncology, Arthritis, Immune and Inflammatory Disorders (AIID) 55
6.3 Competitive Analysis Forecast 56
6.3.1 Competition between Similar Products 57
6.3.2 Competitive Factors 58
6.4 Conclusions 58
6.4.1 A Rocky Road 58
6.4.2 The Only Solution to High Medical Costs is Research 59


For more information please contact :

http://www.aarkstore.com/reports/Therapeutic-Monoclonal-Antibodies-Markets-19638

http://blogs.aarkstore.com/

From:Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
URL: www.aarkstore.com

Post a comment
Write a comment:

Related Searches